Kyntra Bio Slashes Royalty Obligations by $60M, Extends Cash Runway to Q4 2027
KYNB sits 21% above its 52-week low of $6.32.
Summary
Kyntra Bio restructured its royalty financing with NQ Project Phoebus, cutting maximum future payments from $125M to $65M via a $42.6M upfront payment. The deal reduces total liabilities by roughly $80M when combined with the FibroGen Europe bankruptcy settlement, and pro forma cash stands at $53.1M with runway into Q4 2027. This follows the Q2 10-Q that disclosed a Nasdaq delisting notice and a $30.9M bankruptcy gain, so the balance sheet cleanup is material for a company with a $31.5M market cap. The company also reiterated Phase 2 FG-3246 interim data expected in Q4 2026 and a pivotal roxadustat Phase 3 start in Q4 2026. The upfront payment consumes nearly half of reported cash, but the liability reduction and extended runway are net positives for solvency.
At the time of this announcement, KYNB was trading at $7.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.5M. The 52-week trading range was $6.32 to $12.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.